KLK3 and prostate carcinoma: Therefore, prostate cancer cells can still survive at castrated testosterone level and develop into castration-resistant prostate cancer.[4] In our case, after 12 months of combined androgen blockade treatment, the PSA level of this patient was increased significantly and developed into metastatic castration-resistant prostate cancer (mCRPC), and the progression time was short and the development speed was fast, which may be related to the patient's higher Gleason score.